UCB Data Reinforce Long-Term Promise For Weak Muscles Disorder - UCB SA NPV by UCB S.A. (OTC:UCBJF), UCB

UCB S.A.

(OTC:UCBJY) (OTC:UCBJF) on Wednesday presented new data at the International Congress on Neuromuscular Diseases 2026 showing that long-term treatment with rozanolixizumab and zilucoplan delivered sustained improvements across a broad range of symptoms in adults with generalized myasthenia gravis (gMG). gMG is a chronic autoimmune disorder where immune proteins attack the communication between nerves and muscles.

The company also shared findings supporting the usability of its newly approved zilucoplan pre-filled pen.

Rozanolixizumab Demonstrates Durable Symptom Improvements A pooled post hoc analysis of the Phase 3 MycarinG study and its open-label extensions evaluated repeated symptom-driven rozanolixizumab treatment cycles in 129 adults with gMG who received at least two treatment cycles.

The analysis found consistent improvements in both clinician- and patient-reported measures of double vision and eyelid drooping across up to 13 treatment cycles.